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Objective:  More  tolerable  treatment  options  are needed  for  the  large  number  of  elderly  patients  with
non-small-cell  lung  cancer  (NSCLC).  An  analysis  of the  phase  IV POLARSTAR  surveillance  study  examined
the  safety  and  efﬁcacy  of  erlotinib  in  elderly  Japanese  patients  with previously  treated  NSCLC.
Materials  and  methods:  From  December  2007  to October  2009,  all  erlotinib-treated  patients  with  unre-
sectable,  recurrent/advanced  NSCLC  in  Japan  were  enrolled.  Efﬁcacy  and  safety  data  were  stratiﬁed
by  age  (<75  years,  75–84  years,  ≥85  years).  Kaplan–Meier  methodology  was used  to  estimate  median
progression-free  survival  (PFS).  Safety  data  were  collected  with  a focus  on interstitial  lung  disease  (ILD).
Results:  A total  of  9907  patients  were  eligible  for  safety  assessment  (<75  years,  n  = 7848;  75–84  years,
n  =  1911;  ≥85  years,  n  = 148)  and  9651  for efﬁcacy  assessment  (<75  years,  n =  7701;  75–84  years,  n  =  1815;
≥85  years,  n  = 135).  Other  baseline  characteristics  were  balanced.  The  incidence  of ILD  (all  grades)  was
4.2%  (<75  years),  5.1%  (75–84  years),  and  3.4%  (≥85  years).  The  mortality  rate  due to ILD  was  ≤1.7%  in
all age  groups.  Other  toxicities  (including  rash)  were  similar  between  age  groups.  The  median  PFS was
65  days  (95%  conﬁdence  interval  [CI],  62–68)  for  patients  aged  <75  years,  74  days  (95% CI,  69–82)  for
patients  aged  75–84  years,  and  72  days  (95%  CI,  56–93)  for patients  aged  ≥85  years.
Conclusions:  Efﬁcacy  and  tolerability  of  erlotinib  for elderly  patients  was  not  numerically  inferior  to  that
reported  in  younger  patients.  Erlotinib  could  be  considered  for elderly  patients  with  recurrent/advanced
NSCLC.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
An increase in life expectancy in the general population has led
o a rise in the incidence of lung cancer in elderly patients. In the
SA, almost half (47%) of all lung cancer patients are more than
0 years old, and 14% are more than 80 years old [1]. By the same
oken, in Japan, the number of elderly patients diagnosed with lung
ancer is increasing [2], with almost half of all Japanese patients
ith non-small-cell lung cancer (NSCLC) reported as 75 years or
∗ Corresponding author. Tel.: +81 86 422 0210; fax: +81 86 421 3424.
E-mail addresses: hirotin@kchnet.or.jp, hirotinhirotin0826@mail.goo.ne.jp
H. Yoshioka).
ttp://dx.doi.org/10.1016/j.lungcan.2014.09.015
169-5002/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
older [3]. Compared with younger patients, elderly patients with
NSCLC are often considered unﬁt for standard chemotherapy due
to increased chemotherapy-related toxicity, more comorbidities,
and the consequent deterioration in quality of life. Elderly patients
are often underrepresented in clinical trials [4–6], and therefore
validated treatment options remain limited.
Erlotinib (Tarceva®, Chugai Pharmaceutical Co. Ltd., Tokyo,
Japan) is an epidermal growth factor receptor (EGFR) tyrosine-
kinase inhibitor (TKI), which has demonstrated survival beneﬁts
with good tolerability in patients with previously treated NSCLC. In
the pivotal phase III BR.21 global study, erlotinib signiﬁcantly pro-
longed overall survival (OS) compared with placebo in patients with
advanced NSCLC who had received at least one line of chemother-
apy [7]. Promising survival data were reported in two Japanese
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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hase II trials of erlotinib in patients with previously treated
dvanced NSCLC [8,9], leading to the 2007 approval in Japan of
rlotinib for the treatment of patients with recurrent/advanced
SCLC after failure on at least one prior chemotherapy regimen.
rlotinib was well tolerated in the Japanese phase II studies and the
R.21 study, with rash and diarrhea (generally mild or moderate)
eing the most common adverse events (AEs) [7–10].
Given the good tolerability of erlotinib compared with cyto-
oxic agents, the EGFR TKI was expected to be a valid treatment
ption for elderly patients with previously treated NSCLC. The
R.21 study was reanalyzed based on age, speciﬁcally looking at
hether patients were ≥70 years of age at the time of enrollment
nto the trial [11]. Across age groups, similar survival beneﬁts of
rlotinib compared with placebo were reported; however, elderly
atients had signiﬁcantly more overall and grade 3/4 toxicity than
ounger patients, and were more likely to discontinue treatment.
urthermore, in exploratory analyses of the BATTLE study, in which
atients with pretreated NSCLC were randomized to four separate
hase II targeted therapies including erlotinib monotherapy, clin-
cal outcomes of patients aged >65 years were comparable with
hose of younger patients [12].
POLARSTAR (POst-Launch All-patient-Registration Surveillance
n TARceva®-treated NSCLC patients) was a large-scale surveillance
rogram, including all Japanese patients with NSCLC treated with
rlotinib [13]. The study was undertaken as a post-approval com-
itment to monitor the efﬁcacy and safety of erlotinib in Japanese
atients, and more than 10,000 patients were registered. The pri-
ary endpoints were patterns of occurrence of interstitial lung
isease (ILD) and risk factors for onset of ILD, given the small but
mportant risk in Japanese patients [8–10]. Interim safety and efﬁ-
acy data supported the clinical beneﬁts of erlotinib in Japanese
SCLC patients, with no new safety signals observed [13]. ILD (all
rades) was conﬁrmed in 4.5% of the interim analysis population
ith a mortality rate of 1.6%. Signiﬁcant ILD risk factors included
oncomitant or previous ILD, smoking history, concomitant or pre-
ious lung infection, and Eastern Cooperative Oncology Group
ECOG) performance status (PS) 2–4. The median progression-free
urvival (PFS) and OS were 64 and 260 days, respectively.
The present analysis of the POLARSTAR surveillance study com-
ared the efﬁcacy and safety of erlotinib treatment for elderly
stratiﬁed as ≥75 years or 75–84 years or ≥85 years) versus non-
lderly (<75 years) Japanese patients with NSCLC.
. Materials and methods
.1. Study design
All patients with unresectable, recurrent and/or advanced
SCLC who were treated with erlotinib in Japan between December
007 and October 2009 were enrolled. Eligible patients received
ral erlotinib (150 mg  once daily) from 1027 institutions that could
rescribe erlotinib (up to 12 October 2009) and were monitored
ntil erlotinib therapy termination or completion of 12 months of
reatment. The study was conducted in accordance with relevant
ational and local guidelines, and with ethics committee approval.
.2. Assessments
Demographic and baseline data were collected for each patient,
ncluding age, gender, body mass index, tumor histology, ECOG PS,
moking history, and medical history (including hepatic dysfunc-
ion, renal dysfunction, cardiovascular disease, and lung disorders).
afety data were collected at 1, 6, and 12 months after the start of
rlotinib therapy. All AE reports were collected and graded using
he National Cancer Institute Common Terminology Criteria forer 86 (2014) 201–206
Adverse Events (NCI-CTCAE) version 3.0 and coded using the Med-
ical Dictionary for Regulatory Activities (MedDRA) version 14.1
thesaurus terms.
2.3. Outcome measures
PFS was  a secondary endpoint and was assessed according to
routine clinical assessment by each physician. PFS was deﬁned as
the time from the start of erlotinib administration to disease pro-
gression (or death for patients without disease progression who
died from any cause). Efﬁcacy analyses were stratiﬁed by age (<75
years vs. 75–84 years and ≥85 years or ≥75 years), previous treat-
ment (geﬁtinib vs. no geﬁtinib), and ECOG PS (PS 0–2 vs. PS 3–4).
2.4. Statistical analyses
The safety population comprised all patients who received
erlotinib and had a case report form data available. The efﬁcacy
population comprised all patients included in the safety population,
except those where erlotinib therapy was  prescribed off-label (ﬁrst
line) at the time of this study, or where a patient’s therapeutic his-
tory was  unknown. Median PFS was estimated using Kaplan–Meier
methodology. Patients without data for the duration of the observa-
tion period or from the time of treatment initiation were excluded
from analyses of PFS. Statistical analyses were performed using Sta-
tistical Analysis Software version 9.1. The log-rank test was  used to
generate P values.
3. Results
3.1. Patients
Of 10,708 patients registered, the full safety population of the
POLARSTAR study comprised 9909 patients. Of these, 9907 were
eligible for safety assessment in this analysis. A total of 7848 (79.2%)
patients were aged <75 years, 1911 (19.3%) were aged 75–84 years,
and 148 (1.5%) were aged ≥85 years. A total of 9651 patients were
eligible for efﬁcacy assessment and, of these, 7701 (79.8%) were
aged <75 years, 1815 (18.8%) were aged 75–84 years, and 135 (1.4%)
were aged ≥85 years. Baseline characteristics were well balanced
between the age groups (Table 1).
3.2. Erlotinib dose
In regard to the average daily dose of erlotinib, the mean value
for each patient group was slightly lower in patients aged ≥85 years
(130 mg)  compared with patients aged <75 years (140 mg)  or 75–84
years (135 mg); however, the median value was equal (150 mg)
between the age groups. Median duration of erlotinib administra-
tion was  55 days, 57 days, and 50.5 days for patients aged <75 years,
75–84 years, and ≥85 years, respectively (Supplementary Table SI).
The numbers of patients who  required erlotinib dose interruptions
and/or reductions were comparable (Supplementary Table SII).
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.lungcan.
2014.09.015.
3.3. Safety
The incidence of ILD (all grades) was 4.2% in patients aged <75
years, 5.1% in patients aged 75–84 years, and 3.4% in patients aged
≥85 years (Table 2). The mortality rate due to ILD was  1.5% in
patients aged <75 years, 1.7% in patients aged 75–84 years, and
1.4% in patients aged ≥85 years. Nonhematologic toxicities were
generally similar between groups (Table 2). Grade 1–4 hematologic
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Table  1
Baseline characteristics of the safety population by the three predeﬁned age categories.
n (%) Total (N = 9907) <75 years(n = 7848) 75–84 years(n = 1911) ≥85 years(n = 148)
Gender
Male 5298 (53.5) 4253 (54.2) 987 (51.7) 58 (39.2)
Female 4609 (46.5) 3595 (45.8) 924 (48.4) 90 (60.8)
Histology
Adenocarcinoma 7948 (80.2) 6355 (81.0) 1474 (77.1) 119 (80.4)
Nonadenocarcinoma 1935 (19.5) 1475 (18.8) 432 (22.6) 28 (18.9)
Unknown 24 (0.2) 18 (0.2) 5 (0.3) 1 (0.7)
Stage
Recurrence 3316 (33.5) 2584 (32.9) 688 (36.0) 44 (29.7)
IIIB  1385 (14.0) 1013 (12.9) 341 (17.8) 31 (20.9)
IV  4917 (49.6) 4069 (51.8) 790 (41.3) 58 (39.2)
Other  289 (2.9) 182 (2.3) 92 (4.8) 15 (10.1)
Number of previous regimens
0  220 (2.2) 116 (1.5) 91 (4.8) 13 (8.8)
1  2480 (25.0) 1722 (21.9) 667 (34.9) 91 (61.5)
≥2  7182 (72.5) 5990 (76.3) 1148 (60.1) 44 (29.7)
Unknown 25 (0.3) 20 (0.3) 5 (0.3) 0 (0.0)
Presence of brain metastases
No 6608 (66.7) 4946 (63.0) 1531 (80.1) 131 (88.5)
Yes  3259 (32.9) 2874 (36.6) 370 (19.4) 15 (10.1)
Unknown 40 (0.4) 28 (0.4) 10 (0.5) 2 (1.4)
History of geﬁtinib
No 5446 (55.0) 4332 (55.2) 1049 (54.9) 65 (43.9)
Yes  4394 (44.3) 3466 (44.2) 845 (44.2) 83 (56.1)
Unknown 67 (0.7) 50 (0.6) 17 (0.9) 0 (0.0)
ECOG  PS
0–1 7313 (73.8) 5794 (73.8) 1424 (74.5) 95 (64.2)
2  1786 (18.0) 1403 (17.9) 351 (18.4) 32 (21.6)
3–4  790 (8.0) 640 (8.2) 129 (6.8) 21 (14.2)
Unknown 18 (0.2) 11 (0.1) 7 (0.4) 0 (0.0)
Smoking status
No 4366 (44.1) 3369 (42.9) 905 (47.4) 92 (62.2)
Yes  5365 (54.2) 4356 (55.5) 955 (50.0) 54 (36.5)
Unknown 176 (1.8) 123 (1.6) 51 (2.7) 2 (1.4)
Concurrent or previous ILD
No 9483 (95.7) 7522 (95.8) 1816 (95.0) 145 (98.0)
Yes  424 (4.3) 326 (4.2) 95 (5.0) 3 (2.0)
Concurrent or previous COPD
No 8931 (90.1) 7167 (91.3) 1630 (85.3) 134 (90.5)
Yes  866 (8.7) 607 (7.7) 247 (12.9) 12 (8.1)
Unknown 110 (1.1) 74 (0.9) 34 (1.8) 2 (1.4)
Concurrent or previous lung infection
No 9173 (92.6) 7319 (93.3) 1720 (90.0) 134 (90.5)
Yes  615 (6.2) 450 (5.7) 153 (8.0) 12 (8.1)
0) 38 (2.0) 2 (1.4)
A ative Oncology Group; ILD, interstitial lung disease; PS, performance status.
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bbreviations: COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooper
oxicities (neutropenia, leukopenia, anemia, and thrombocyto-
enia) were observed at <1.0% in each group. One patient had grade
 anemia (<75 year age group) and one patient had grade 5 throm-
ocytopenia (75–84 year age group).
.4. Efﬁcacy, measured by PFS
The median PFS for patients aged <75 years was 65 days (95%
onﬁdence interval [CI], 62–68) compared with 74 days (95% CI,
9–82) for patients aged ≥75 years (P = 0.0002; Fig. 1). When the
lderly group was analyzed further, the median PFS for patients
ged 75–84 years and ≥85 years was 74 days (95% CI, 69–82) and
2 days (95% CI, 56–93), respectively (P = 0.0010; Fig. 2).
In patients with clinical features associated with better EGFR
KI efﬁcacy (i.e. adenocarcinoma, nonsmoking status, ECOG PS 0–2,
nd second-/third-line treatment setting) who had not previously
eceived geﬁtinib, the median PFS was 176 days (95% CI, 152–198)
or patients aged <75 years, 213 days (95% CI, 172–261) for patients
ged 75–84 years, and 341 days (95% CI, 205–not reached) for
atients aged ≥85 years (P = 0.0896; Fig. 3A). In patients with clin-
cal features associated with better EGFR TKI efﬁcacy (as described
arlier) who had previously received geﬁtinib, the median PFS was
00 days (95% CI, 91–109) for patients aged <75 years, 108 days (95%
Time (days)
Fig. 1. PFS for two  different patient age groups (<75 years vs. ≥75 years) in the
POLARSTAR study. Abbreviations:  CI, conﬁdence interval; PFS, progression-free sur-
vival.
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Table 2
Adverse events.
n (%) Total <75 years 75–84 years ≥85 years
(n  = 9907) (n = 7848) (n = 1911) (n = 148)
ILD
All grades 429 (4.3) 327 (4.2) 97 (5.1) 5 (3.4)
Grade  ≥3 251 (2.5) 193 (2.5) 55 (2.9) 3 (2.0)
Grade  5 153 (1.5) 119 (1.5) 32 (1.7) 2 (1.4)
Skin  disorder
All grades 6673 (67.4) 5350 (68.2) 1242 (65.0) 81 (54.7)
Grade  ≥3 742 (7.5) 591 (7.5) 144 (7.5) 7 (4.7)
Grade  5 3 (<0.1) – 2 (0.1) 1 (0.7)
Hepatic function disorder
All grades 976 (9.9) 784(10.0) 181 (9.5) 11 (7.4)
Grade  ≥3 174 (1.8) 146 (1.9) 28 (1.5) –
Grade  5 6 (0.1) 5 (0.1) 1 (0.1) –
Diarrhea
All  grades 2133 (21.5) 1658 (21.1) 439 (23.0) 36 (24.3)
Grade  ≥3 128 (1.3) 99 (1.2) 28 (1.5) 1 (0.7)
Grade  5 2 (<0.1) 1 (<0.1) 1 (0.1) –
Fatigue
All  grades 254 (2.6) 190 (2.4) 59 (3.1) 5 (3.4)
Grade  ≥3 39 (0.4) 24 (0.3) 14 (0.7) 1 (0.7)
Nausea
All  grades 290 (2.9) 239 (3.0) 49 (2.6) 2 (1.4)
Grade  ≥3 33 (0.3) 27 (0.3) 6 (0.3) –
Vomiting
All  grades 164 (1.7) 135 (1.7) 25 (1.3) 4 (2.7)
Grade  ≥3 17 (0.2) 14 (0.2) 3 (0.2) –
Increased AST/ALT
All grades 139 (1.4) 117 (1.5) 21 (1.1) 1 (0.7)
Grade  ≥3 17 (0.2) 16 (0.2
AE, adverse event; AST/ALT, aspartate aminotransferase/alanine aminotransferase; ILD, in
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wig. 2. PFS for three different patient age groups (<75 years vs. 75–84 years vs.
85  years) in the POLARSTAR study. Abbreviations:  CI, conﬁdence interval; PFS,
rogression-free survival.
I, 92–126) for patients aged 75–84, and 70 days (95% CI, 56–103)
or patients aged ≥85 years (P = 0.2344; Fig. 3B).
The median PFS for patients with ECOG PS 0–2 was 71 days (95%
I, 68–74) for patients aged <75 years, 80 days (95% CI, 73–88) for
atients aged 75–84, and 80 days (95% CI, 66–117) for patients aged
85 years (Fig. 4A). The median PFS for patients with ECOG PS 3–4
as 24 days (95% CI, 22–28) for patients aged <75 years, 25 days
95% CI, 22–37) for patients aged 75–84 years, and 27 days (95% CI,
3–37) for patients aged ≥85 years (Fig. 4B).. Discussion
The POLARSTAR study included a high number of patients who
ere ≥75 years old and eligible for inclusion in the safety and) 1 (0.1) –
terstitial lung disease.
efﬁcacy analysis. The incidence of hematologic and nonhematologic
toxicity was  comparable between older and younger patients. Rash,
a well-known side effect of erlotinib treatment, was neither more
common nor more severe in elderly patients, conﬁrming previous
studies suggesting age is not a predictor of rash [14].
ILD, a rare but potentially serious drug-related complication, has
been reported in approximately 5% of erlotinib-treated Japanese
patients with around half of these cases being fatal [8–10]. The
incidence of ILD, primary endpoint of the POLARSTAR study, was
similar between age groups and was  comparable with that previ-
ously reported in Japanese patients [8–10]. The results of a previous
multivariate analysis of the POLARSTAR study data showed that
concurrent or previous ILD; smoking status; concurrent or previ-
ous emphysema or chronic obstructive pulmonary disease (COPD);
period from initial diagnosis to start of treatment; concurrent or
previous lung infection; ECOG PS; history of geﬁtinib treatment;
and number of chemotherapy regimens were each signiﬁcant risk
factors for developing ILD [15]. Conversely, age was not identiﬁed
as a risk factor [15], which was consistent with the results of this
exploratory analysis of POLARSTAR by age. Similarly, the mortal-
ity rate due to ILD was  comparable between older and younger
patients, and lower than that reported in previous studies [8–10].
In elderly patients, treatment-related toxicities may  lead to
higher incidences of treatment interruption, compared with
younger patients [16]. It has also been suggested that elderly
patients may  have reduced acceptability of potential deteriorations
in quality of life (e.g. changes driven by toxicity) compared with
younger patients [17]. In this study, there was very little differ-
ence in the mean erlotinib daily dose and the duration of erlotinib
administration between each group. These results suggest that
there was  no signiﬁcant deterioration of erlotinib tolerability in
elderly patients, compared with younger patients.In spite of the lack of strict eligibility criteria in the
present study, which included patients who might otherwise be
excluded from standard prospective clinical trials, the median PFS
reported for elderly patients in POLARSTAR was  similar to that
H. Yoshioka et al. / Lung Cancer 86 (2014) 201–206 205
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reviously reported in the BR.21 study [7], and in the phase II stud-
es of erlotinib in Japanese patients [8,9]. When older and younger
atients were compared, the median PFS for older patients was
lightly longer than that reported for their younger counterparts.
he P value was exploratory only, and therefore a signiﬁcant dif-
erence was not claimed. However, this along with the median PFS
ata, served to conﬁrm that there was no apparent reduction in
he efﬁcacy of erlotinib in elderly patients, compared with younger
atients.
Some clinical features (e.g. PS, history of geﬁtinib use) are
hought to inﬂuence erlotinib efﬁcacy. To investigate whether these
actors had a bearing on the results seen in the efﬁcacy analysis car-
ied out in this study, subgroup analyses were performed for ECOG
S and history of geﬁtinib use. Similar results to the overall efﬁ-
acy analyses were observed for younger and older patients in all
ubgroup analyses.
In the POLARSTAR study, patients were of unknown EGFR
utation status. Previous studies have demonstrated signiﬁcant
fﬁcacy beneﬁts and similar safety results for erlotinib-treated
apanese patients with NSCLC bearing an EGFR mutation, com-
ared with patients with wild-type EGFR [18]. No prospective
ata evaluating erlotinib efﬁcacy and safety in elderly patientsFig. 4. PFS for patients with ECOG PS (A), 0–2 and (B), 3–4. Abbreviations: CI, conﬁ-
dence interval; EGOG, Eastern Cooperative Oncology Group; PFS, progression-free
survival; PS, performance status.
with EGFR mutation-positive NSCLC (especially patients ≥ 75 years)
are available. Some older patients in the POLARSTAR surveillance
study were treated with erlotinib for long periods of time (some
patients in each age group received erlotinib for 360 days or
more), raising the possibility that some of these patients may  have
EGFR mutation-positive disease. These surveillance data suggest
that, even in older patients with EGFR mutation-positive disease,
erlotinib could be effective, tolerable, and administered over long
periods of time.
Overall, these analyses were supportive of the safety and efﬁcacy
of erlotinib in elderly (≥75 years) patients. However, these data
should be assessed in light of the limitations of the study. This was
a single-arm surveillance study with no control group, no strictly
deﬁned period of observation, and no patient selection criteria. The
duration of tumor response assessment was not deﬁned because
the primary endpoint of POLARSTAR was  to identify the onset of
interstitial lung disease and to examine the factors that seem to
affect occurrence in Japan. In the POLARSTAR study population,
20.8% of the patients were ≥75 years old; given the high proportion
of elderly lung cancer patients in the general population in Japan
and worldwide, this number was  lower than might be expected,
which suggested that some potential selection bias for age existed.
However, as the study includes all patients who  received erlotinib
over a 23-month period, including patients with poor ECOG PS and
comorbidities who would usually be excluded from clinical trials,
2 g Canc
i
d
5
y
t
b
o
R
m
b
h
t
C
o
D
L
S
A
o
P
w
d
R
[
[
[
[
[
[
[
[06 H. Yoshioka et al. / Lun
t can be considered to reﬂect real-world clinical practice in Japan
uring the study period.
. Conclusion
The efﬁcacy of erlotinib treatment for elderly patients (≥75
ears) with previously treated NSCLC was not numerically inferior
o that seen in younger patients, and the tolerability was similar
etween age groups. Erlotinib could be considered as a treatment
ption for elderly patients with NSCLC, as for younger patients.
ole of funding source
This trial was designed, funded, and monitored by Chugai Phar-
aceutical Co., Ltd. Data were gathered, analyzed, and interpreted
y Chugai with input from all authors. The corresponding author
ad full access to the relevant data and took full responsibility for
he ﬁnal decision to submit the report for publication.
onﬂicts of interest statement
Dr Yoshioka, Komuta, and Imamura received honoraria outside
f this study from Chugai Pharmaceuticals Co. Ltd. Dr Fukuoka and
r Kudoh received personal fees from Chugai Pharmaceuticals Co.
td. as members of an independent advisory board for erlotinib. Mr
eki is an employee of Chugai Pharmaceuticals Co. Ltd.
cknowledgements
Medical writing assistance was provided by Emma  McConnell
f Gardiner-Caldwell Communications, and was funded by Chugai
harmaceutical Co. Ltd. The authors would like to thank all patients
ho participated in the study and clinical personnel involved in
ata collection.
eferences
[1] Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE,  Taioli E, et al. Lung
cancer in elderly patients: an analysis of the surveillance, epidemiology, and
end results database. J Clin Oncol 2007;25:5570–7.
[2] Katanoda K, Yako-Suketomo H. Time trends in lung cancer mortality between
1950 and 2008 in Japan, USA and Europe based on the WHO  mortality database.
Jpn  J Clin Oncol 2011;41:1046–7.
[er 86 (2014) 201–206
[3] Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al.
Cancer incidence and incidence rates in Japan in 2007: a study of 21
population-based cancer registries in the monitoring of cancer incidence in
Japan (MCIJ) project. Jpn J Clin Oncol 2013;43:328–36.
[4] Hutchins LF, Unger JM,  Crowley JJ, Coltman Jr CA, Albain KS. Underrepresenta-
tion  of patients 65 years of age or older in cancer-treatment trials. N Engl J Med
1999;341:2061–7.
[5] Lewis JH, Kilgore ML,  Goldman DP, Trimble EL, Kaplan R, Montello MJ,  et al.
Participation of patients 65 years of age or older in cancer clinical trials. J Clin
Oncol 2003;21:1383–9.
[6] Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials
for cancer drug registration: a 7-year experience by the US Food and Drug
Administration. J Clin Oncol 2004;22:4626–31.
[7] Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S,
et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med
2005;353:123–32.
[8] Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K,
et al. Efﬁcacy and safety of erlotinib monotherapy for Japanese patients with
advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:
1439–45.
[9] Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M,  Horai T, et al. Phase
II study of erlotinib in Japanese patients with advanced non-small cell lung
cancer. Anticancer Res 2010;30:557–63.
10] Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y,
et  al. Phase I dose-ﬁnding and pharmacokinetic study of the oral epider-
mal  growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in
Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008;61:
489–96.
11] Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for
advanced non-small cell lung cancer in the elderly: an analysis of the National
Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol
2008;26:2350–7.
12] Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, et al. Clinical outcomes
and biomarker proﬁles of elderly pretreated NSCLC patients from the BATTLE
trial. J Thorac Oncol 2012;7:1645–52.
13] Nakagawa K, Kudoh S, Ohe Y. Postmarketing surveillance study of erlotinib in
Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis
of  3488 patients (POLARSTAR). J Thorac Oncol 2012;7:1296–303.
14] Giuliani J, Marzola M.  Skin rash during erlotinib for advanced non-small cell
lung cancer: is age a clinical predictor. Arch Dermatol Res 2013;305:653–8.
15] Kuwano K, Kudoh S, Ando M,  Ohe Y, Nakagawa K, Yamazaki N, et al. Inves-
tigation of risk factors for developing interstitial lung disease (ILD) and poor
prognostic factors for ILD death in Japanese patients with non-small-cell lung
cancer (NSCLC): a ﬁnal analysis of a large-scale erlotinib surveillance study
(POLARSTAR). J Thorac Oncol 2013;8(Suppl 2):S142–3. Abstract O03.07.
16] Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL. Survival rates and tol-
erability of platinum-based chemotherapy regimens for elderly patients with
non-small-cell lung cancer (NSCLC). Lung Cancer 2006;53:171–6.
17] Yellen SB, Cella DF, Leslie WT.  Age and clinical decision making in oncology
patients. J Natl Cancer Inst 1994;86:1766–70.18] Goto K, Nishio M,  Yamamoto N, Chikamori K, Hida T, Maemondo M,
et  al. A prospective, phase II, open-label study (JO22903) of ﬁrst-line
erlotinib in Japanese patients with epidermal growth factor receptor (EGFR)
mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer
2013;82:109–14.
